Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein

US10035844B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Peter Kwong · Washington, US
• Gary J. Nabel · Cambridge, US
• Rebecca S. Rudicell · Cumberland, US
• John Mascola · Rockville, US
• Mark Connors · Bethesda, US
• Ivelin Georgiev · Nashville, US
• Jiang Zhu · San Ramon, US
• Young Do Kwon · Bethesda, US
• Tongqing Zhou · Boyds, US
• Yongping Yang · Potomac, US
• Baoshan Zhang · Bethesda, US
• Gwo-Yu Chuang · Rockville, US
• Xueling Wu · Potomac, US
• Zhi-yong Yang · Potomac, US
• Wei Shi · 安丰镇, CN

Key dates

• Filing date: Jun 2, 2017
• Grant date: Jul 31, 2018
• Expiry date: Jun 2, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.